Table IV.
Summary of GRADE findings for corticosteroids
| Outcomes | Estimated effect | Number of participants | Certainty of the evidence | Comments |
|---|---|---|---|---|
| Participant complete remission | 18%-63% (2 studies) | 110 (2 studies) | Low | Stage IA: 18%, IB: 22% (Kartan 2019) T1 disease: 63%, T2: 25% (Zackheim 1998) |
| Participant partial remission | 31%-67% (2 studies) | 110 (2 studies) | Low | Stage IA: 32%, IB 67% (Kartan 2019) T1: 31%, T2: 57% (Zackheim 1998) |
| Mean reduction in lesion counts/body surface area (BSA) from baseline to assessment | Not estimable, lack of data | No studies addressed this outcome. | ||
| Investigator/physician global assessment | Not estimable, lack of data | No studies addressed this outcome. | ||
| Participants global assessment | Not estimable, lack of data | No studies addressed this outcome. | ||
| Quality of life | Not estimable, lack of data | No studies addressed this outcome. | ||
| Adverse effect estimates | See comment | 79 (1 study) | Very low | Temporary minor irritation (2); Atrophy (1); Stretch marks (1); Temporary serum cortisol below lower limit of normal (T1 = 4 patients, T2 = 6 patients) (Zackheim 1998) |
BSA, Body surface area; GRADE, Grading Recommendations Assessment, Development and Evaluation.